Antibiotic Artisan

February 2011
Forbes Asia;Feb2011, Vol. 7 Issue 2, p72
The article informs that chemist William DeGrado from the University of Pennsylvania with the help of a powerful supercomputer simulation, has created new antibiotics. It has been stated that antibiotics developed by him can be made with standard chemistry techniques. It has been stated that the first antibiotic developed by DeGrado in 2002 is now in human trials at the biotech firm PolyMedix. Molecular modeling expert Michael Klein has devised a supercomputer simulation to help De-Grado.


Related Articles

  • PolyMedix Extends Cash Runway with Modest $21M Public Offering. Hollingsworth, Catherine // BioWorld Today;11/12/2009, Vol. 20 Issue 219, p1 

    The article reports on the 21 million U.S. dollars public offering of PolyMedix Inc. in November 2009. Proceeds of the offering, priced at 1 U.S. dollar per unit, will be used to advance its clinical trials of the antibiotic PMX-30063 and heparin antagonist PMX-60056, as well as for general...

  • CLINIC ROUNDUP.  // BioWorld Today;5/12/2008, Vol. 19 Issue 92, p2 

    This section offers news briefs concerning clinical trials. The accrual time for the Phase III study of the investigational chemosensitizing drug phenoxodiol called Ovarian Tumor Response (OVATURE) has been lengthened by Marshall Edwards Inc. Enrollment of patients for a trial of intravenous...

  • Other News To Note.  // BioWorld Today;5/20/2011, Vol. 22 Issue 98, p2 

    The article presents an update on issues related to biotechnology as of May 21, 2011. BioAegis Therapeutics Inc. has entered a partnership agreement with Brigham and Women's Hospital for rights to a technology involving the endogenous human protein, plasma gelsolin (pGSN). Enzon Pharmaceuticals...

  • PolyMedix PMX-30063 Defensin-Mimetic Antibiotic Compound Shows Promising Activity for Oral Mucositis.  // Biomedical Market Newsletter;5/17/2011, p167 

    The article focuses on the ability of PMX-30063, a lead defensin-mimetic antibiotic compound from PolyMedix Inc., to mitigate ulcerative mucositis when administered as an oral rinse. It states that PMX-30063 is in the Phase 2 clinical trial for treating patients with acute bacterial skin and...

  • PolyMedix Presents Clinical and Pre-Clinical Data on PMX-30063 Defensin-Mimetic Antibiotic at ECCMID 2011 Meeting.  // Biomedical Market Newsletter;5/16/2011, p255 

    The article reports on the clinical data presentation of PolyMedix Inc.'s PMX-30063 antibiotic at the 2011 European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Milan, Italy. It says that the presentation, "Investigation of Potential Mechanisms Underlying Transient...

  • CLINIC ROUNDUP.  // BioWorld Today;6/8/2009, Vol. 20 Issue 108, p2 

    This section offers news briefs on clinical trials. A Phase III study of rolofylline in acute heart failure failed to reach its endpoints, according to Merck & Co. Inc. A new drug application was submitted by Somaxon Pharmaceuticals Inc. to the U.S. Food and Drug Administration for Silenor which...

  • PolyMedix Presents Data Showing Antimicrobial Activity of Sutures Containing PolyCide.  // Biomedical Market Newsletter;7/5/2011, p510 

    The article focuses on the clinical results presented by PolyMedix Inc., an emerging biotechnology company regarding the antimicrobial activity of sutures which contains polycide. It states that PolyMedix Inc. presented a data which shows that its PolyCide(r) materials are active agents for...

  • PolyMedix Successfully Completes Phase 1 Exposure Escalation Safety Study With PMX-30063 Antibiotic.  // Biomedical Market Newsletter;3/14/2011, p24 

    The article reports on the completion of PolyMedix Inc.'s Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic PMX-30063 in the U.S. Results show that PMX-30063 may be safely administered at a high dose for more than five days. Findings also reveal that very...

  • Klein Leaves Citi After 23 Years. J. H. // Mergers & Acquisitions Report;7/28/2008, Vol. 21 Issue 30, p4 

    The article announces the retirement of Michael Klein as chairman of Citi group's International Clients Group.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics